Get the Stockscreener App
8.78
5.02%
0.42
After Hours:
8.75
-0.03
-0.34%
Kyverna Therapeutics Inc stock is traded at $8.78, with a volume of 1.10M.
It is up +5.02% in the last 24 hours and up +19.78% over the past month.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
See More
Previous Close:
$8.36
Open:
$8.56
24h Volume:
1.10M
Relative Volume:
1.60
Market Cap:
$384.53M
Revenue:
-
Net Income/Loss:
$-110.66M
P/E Ratio:
-2.8356
EPS:
-3.0963
Net Cash Flow:
$-97.76M
1W Performance:
+12.56%
1M Performance:
+19.78%
6M Performance:
+153.76%
1Y Performance:
+96.86%
1-Day Range:
$8.45
$9.75
1-Week Range:
$7.62
$9.75
52-Week Range:
$1.78
$9.75
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Name
Kyverna Therapeutics Inc
Sector
Industry
Phone
(510) 626-8331
Address
5980 HORTON STREET, EMERYVILLE
Compare KYTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.78 | 366.14M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| May-27-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-10-24 | Initiated | UBS | Buy |
| Oct-09-24 | Initiated | Rodman & Renshaw | Buy |
| Jul-03-24 | Initiated | H.C. Wainwright | Neutral |
| Mar-04-24 | Initiated | JP Morgan | Overweight |
| Mar-04-24 | Initiated | Leerink Partners | Outperform |
| Mar-04-24 | Initiated | Morgan Stanley | Overweight |
| Mar-04-24 | Initiated | Wells Fargo | Overweight |
View All
Kyverna Therapeutics Inc Stock (KYTX) Latest News
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics (KYTX) Stock Analysis Report | Financials & Insights - Benzinga
Octaware Technologies Limited Added to High Probability Setup ListEvening Star Patterns & Free Navigate Market With Precision - earlytimes.in
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
6 Companies Hanging On in Cell Therapy - BioSpace
Kyverna Therapeutics Inc Stock Analysis and ForecastInflation Impact on Stocks & Breakout Portfolio Performance - earlytimes.in
Aug Gainers: What margin trends mean for Kyverna Therapeutics Inc. stock2025 Key Lessons & Real-Time Chart Pattern Alerts - moha.gov.vn
FY2025 Earnings Estimate for KYTX Issued By HC Wainwright - MarketBeat
Trend Recap: Will Kyverna Therapeutics Inc. stock recover faster than peersJuly 2025 Setups & Long-Term Capital Growth Strategies - BỘ NỘI VỤ
Kyverna Therapeutics, Inc.: A Promising Market Position with KYV-101’s Potential as the First FDA-Approved CAR-T Therapy for Autoimmune Diseases - TipRanks
Why Kyverna Therapeutics Inc. stock remains resilient2025 Volatility Report & Free Technical Confirmation Trade Alerts - newser.com
Palo Alto, Vizsla Silver, NetEase And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
How sentiment analysis helps forecast Kyverna Therapeutics Inc.Portfolio Growth Summary & Consistent Profit Focused Trading Strategies - newser.com
Why Kyverna Therapeutics Inc. stock remains undervaluedJuly 2025 Fed Impact & Daily Stock Trend Reports - newser.com
Is Kyverna Therapeutics Inc. stock attractive for passive investorsWeekly Profit Summary & Verified Entry Point Signals - newser.com
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing (TGTX) - Seeking Alpha
KYTX: KYV-101 delivers transformative results in autoimmune diseases, targeting first-to-market leadership - TradingView
KYTX: KYV101 demonstrates transformative efficacy and safety in autoimmune diseases, targeting first-to-market leadership - TradingView
Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Buyback Activity & Free Safe Capital Growth Stock Tips - newser.com
What analysts say about Kyverna Therapeutics Inc stockVWAP Trading Strategies & Calculate Profit Targets With AI Accuracy - earlytimes.in
What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Rallies & Safe Swing Trade Setup Alerts - newser.com
Kyverna Therapeutics Inc Stock (KYTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):